The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
This biotech has candidates in late-stage clinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback